GoAI
Get started
Verrica Pharmaceuticals Inc. logo

Verrica Pharmaceuticals Inc.

VRCA

NASDAQHealthcareBiotechnology

Open in GoAI

Regular session

$4.7515

−$0.0685 · -1.42%

Aug 24, 12:13 PM ET

VRCA company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Hold

Wait — insufficient conviction to act

Valuation

73

Undervalued

Momentum

42

Neutral

Sentiment

42

Mixed

Risk resilience

31

High Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Verrica Pharmaceuticals Inc., a dermatology therapeutics company, engages in the development and commercialization of medications for the treatment of dermatologic diseases in the United States. The company offers YCANTH (VP-102) a drug-device combination that contains a GMP-controlled formulation of cantharidin for the treatment of molluscum in adult and pediatric patients, as well as for the treatment of common warts. It also develops VP-315, an oncolytic peptide-based injectable therapy that is in phase II clinical trial for the treatment of dermatology oncologic conditions, which include basal cell carcinoma and other dermatological oncology indications. The company has a collaboration and license agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum and common warts in Japan; and a license agreement with Lytix Biopharma AS to develop and commercialize VP-315 for use in malignant and pre-malignant dermatological indications. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania.

Industry
Biotechnology
Sector
Healthcare
Headquarters
US
CEO
Jayson Rieger
Listed since
Jun 15, 2018
Employees
76

Market position

Day range

Current $4.7515

52-week range

Current $4.7515

Open
$4.62
Previous close
$4.82
Volume
25.26K
0.42× average
Average volume
59.88K
Average daily volume
Market cap
81.62M USD
Beta
1.49
Market reference 1
50-day average
$5.5958
-15.09% below average
200-day average
$6.1772
-23.08% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
60.01M USD
P/E (TTM)
-2.73×
P/B (TTM)
23.5×
P/S (TTM)
2.69×
EV / EBITDA
-6.41×
Earnings yield
-20.21%
Free cash flow yield
-19.91%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
85.89%
Operating margin
-92.78%
Net margin
-102.84%
Return on equity
-72.29%
Return on assets
-37.95%
Return on invested capital
-37.97%

Financial health

Debt / equity
0.42×
Current ratio
2.59×
Altman Z-score
-13.28
Piotroski F-score
4 of 9

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends236%-325%-886%-1448%Gross margin, FY2021: 96.07%Gross margin, FY2022: 91.97%Gross margin, FY2023: 85.44%Gross margin, FY2024: 63.79%Gross margin, FY2025: 90.33%Operating margin, FY2021: -257.57%Operating margin, FY2022: -235.78%Operating margin, FY2023: -1283.35%Operating margin, FY2024: -871.25%Operating margin, FY2025: -33.56%Net margin, FY2021: -292.33%Net margin, FY2022: -271.11%Net margin, FY2023: -1307.47%Net margin, FY2024: -1012.15%Net margin, FY2025: -50.27%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 96.07%. Gross margin FY2022 91.97%. Gross margin FY2023 85.44%. Gross margin FY2024 63.79%. Gross margin FY2025 90.33%. Operating margin FY2021 -257.57%. Operating margin FY2022 -235.78%. Operating margin FY2023 -1283.35%. Operating margin FY2024 -871.25%. Operating margin FY2025 -33.56%. Net margin FY2021 -292.33%. Net margin FY2022 -271.11%. Net margin FY2023 -1307.47%. Net margin FY2024 -1012.15%. Net margin FY2025 -50.27%.

Income trends

Revenue

35.58M USD+370.22%

Operating income

−11.94M USD+81.89%

Net income

−17.89M USD+76.64%
Income trends across reported periods46.79M USD1.93M USD−42.93M USD−87.79M USDRevenue, FY2021: 12M USDRevenue, FY2022: 9.03M USDRevenue, FY2023: 5.12M USDRevenue, FY2024: 7.57M USDRevenue, FY2025: 35.58M USDOperating income, FY2021: −30.91M USDOperating income, FY2022: −21.3M USDOperating income, FY2023: −65.76M USDOperating income, FY2024: −65.92M USDOperating income, FY2025: −11.94M USDNet income, FY2021: −35.08M USDNet income, FY2022: −24.49M USDNet income, FY2023: −67M USDNet income, FY2024: −76.58M USDNet income, FY2025: −17.89M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 12M USD. Revenue FY2022 9.03M USD. Revenue FY2023 5.12M USD. Revenue FY2024 7.57M USD. Revenue FY2025 35.58M USD. Operating income FY2021 −30.91M USD. Operating income FY2022 −21.3M USD. Operating income FY2023 −65.76M USD. Operating income FY2024 −65.92M USD. Operating income FY2025 −11.94M USD. Net income FY2021 −35.08M USD. Net income FY2022 −24.49M USD. Net income FY2023 −67M USD. Net income FY2024 −76.58M USD. Net income FY2025 −17.89M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue35.58M USD7.57M USD5.12M USD9.03M USD12M USD
Cost of goods sold3.44M USD2.74M USD746K USD725K USD472K USD
Gross profit32.14M USD4.83M USD4.38M USD8.31M USD11.53M USD
Research and development8.86M USD11.84M USD20.3M USD12.2M USD15.93M USD
Selling, general, and administrative35.22M USD58.82M USD47.31M USD17.41M USD26.98M USD
Operating expenses44.08M USD70.75M USD70.14M USD29.6M USD42.44M USD
Interest income929K USD1.42M USD2.74M USD476K USD123K USD
Interest expense7.74M USD9.41M USD3.96M USD2.17M USD4.3M USD
Depreciation and amortization781K USD1.27M USD836K USD718K USD472K USD
Operating income−11.94M USD−65.92M USD−65.76M USD−21.3M USD−30.91M USD
Net income−17.89M USD−76.58M USD−67M USD−24.49M USD−35.08M USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
45%
5 beats, 6 misses, 0 met estimates
Average EPS surprise
-114.45%
11 comparable reports
Latest EPS result
-0.62
Estimate -0.39 · Miss by 60.00%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates0.21-0.72-1.66-2.59Q1 '25MissQ2 '25BeatQ3 '25BeatQ4 '25BeatQ1 '26MissQ2 '26BeatQ3 '26MissQ4 '26Estimate
Q1 2025, reported Mar 11, 2025: actual -2.4, estimate -0.32, surprise -650.00%, Miss. Q2 2025, reported May 13, 2025: actual -1, estimate -1.23, surprise +18.96%, Beat. Q3 2025, reported Aug 12, 2025: actual 0.02, estimate -0.7, surprise +102.86%, Beat. Q4 2025, reported Nov 14, 2025: actual -0.03, estimate -1.14, surprise +97.37%, Beat. Q1 2026, reported Mar 11, 2026: actual -0.51, estimate -0.43, surprise -18.60%, Miss. Q2 2026, reported May 12, 2026: actual -0.41, estimate -0.59, surprise +30.51%, Beat. Q3 2026, reported Aug 6, 2026: actual -0.62, estimate -0.388, surprise -60.00%, Miss. Q4 2026, reported Nov 13, 2026: actual —, estimate -0.493, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates15.46M10.41M5.35M292.4KQ1 '25MissQ2 '25BeatQ3 '25BeatQ4 '25BeatQ1 '26BeatQ2 '26BeatQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Mar 11, 2025: actual 344K USD, estimate 1.04M USD, surprise -66.97%, Miss. Q2 2025, reported May 13, 2025: actual 3.44M USD, estimate 2.54M USD, surprise +35.65%, Beat. Q3 2025, reported Aug 12, 2025: actual 12.7M USD, estimate 4.27M USD, surprise +197.70%, Beat. Q4 2025, reported Nov 14, 2025: actual 14.34M USD, estimate 9.75M USD, surprise +47.06%, Beat. Q1 2026, reported Mar 11, 2026: actual 5.09M USD, estimate 4.52M USD, surprise +12.65%, Beat. Q2 2026, reported May 12, 2026: actual 5.02M USD, estimate 4.51M USD, surprise +11.27%, Beat. Q3 2026, reported Aug 6, 2026: actual 5.86M USD, estimate 5.73M USD, surprise +2.24%, Beat. Q4 2026, reported Nov 13, 2026: actual —, estimate 6.4M USD, surprise —, Comparison unavailable.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Analyst price target

Average target

$13.25

178.86% upside
Past 12 months12-month forecastHigh $17.00Average $13.25Low $10.00

Rating distribution

10 ratings
Strong buy00%
Buy660%
Hold440%
Sell00%
Strong sell00%

Recent analyst actions

6 institutions
TD CowenmaintainBuy
JefferiesmaintainBuy

VRCA news

marketbeat.com

Verrica Pharmaceuticals Q2 Earnings Call Highlights

Verrica Pharmaceuticals NASDAQ: VRCA reported second-quarter revenue growth in its YCANTH treatment for molluscum contagiosum, while outlining progress in pivotal studies of the product for common warts and announcing a…

Read source
seekingalpha.com

Verrica Pharmaceuticals Inc. (VRCA) Q2 2026 Earnings Call Transcript

Verrica Pharmaceuticals Inc. (VRCA) Q2 2026 Earnings Call Transcript

Read source
globenewswire.com

Verrica Pharmaceuticals to Report Second Quarter 2026 Financial Results and Provide a Corporate Update on August 6, 2026

WEST CHESTER, Pa., July 30, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a therapeutics company developing and commercializing medications for the treatment of…

Read source
globenewswire.com

Verrica Pharmaceuticals and Medomie Pharma Enter into Exclusive Distribution, Marketing and Supply Agreement to Commercialize YCANTH® for the Treatment of Molluscum Contagiosum in Israel

WEST CHESTER, Pa., July 21, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a therapeutics company developing and commercializing medications for the treatment of dermatological…

Read source
globenewswire.com

Verrica Pharmaceuticals Announces First U.S. Patient Dosed in the Second Pivotal Clinical Trial (COVE-3) of its Phase 3 Program Evaluating YCANTH® (VP-102) for the Treatment of Common Warts

- Development Partner Torii Pharmaceutical also recently announced dosing of the first Japanese patient in this trial evaluating YCANTH (TO-208) in Japan - - Verrica maintains ownership of global rights to YCANTH for all…

Read source
globenewswire.com

Verrica Pharmaceuticals Announces First U.S. Patient Dosed in the Second Pivotal Clinical Trial (COVE-3) of its Phase 3 Program Evaluating YCANTH® (VP-102) for the Treatment of Common Warts

– Development Partner Torii Pharmaceutical also recently announced dosing of the first Japanese patient in this trial evaluating YCANTH (TO-208) in Japan –

Read source

Corporate actions

Corporate action history

Stock split

Effective Jul 25, 2025

1:10

VRCA peers

Amgen Inc. logo

AMGN

Amgen Inc.

$441.01

+0.38%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.17

+0.03%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$547.77

-0.05%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$376.6

-0.58%

Sanofi logo

SNY

Sanofi

$45.602

-0.54%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$825.38

-1.04%

ETFs holding VRCA

Funds reporting this stock among their holdings, ordered by reported position size.

Vanguard Morningstar Total Stock Market ETF logoVanguard Morningstar Total Stock Market ETFVTI
Market value
1.13M
Weight
0.00%
AUM
2.3T USD
Expense ratio
0.03%
Price / 1D
$377.56-0.18%
Vanguard Extended Market ETF logoVanguard Extended Market ETFVXF
Market value
707.13K
Weight
0.00%
AUM
93.7B USD
Expense ratio
0.05%
Price / 1D
$243.78-0.71%
iShares Micro-Cap ETF logoiShares Micro-Cap ETFIWC
Market value
177K
Weight
0.01%
AUM
1.53B USD
Expense ratio
0.60%
Price / 1D
$196.82-0.66%
Dimensional - US Small Cap ETF logoDimensional - US Small Cap ETFDFAS
Market value
35.54K
Weight
0.00%
AUM
15.92B USD
Expense ratio
0.26%
Price / 1D
$82.66-0.43%
U.S. Micro Cap Portfolio ETF logoU.S. Micro Cap Portfolio ETFDFMC
Market value
10.15K
Weight
0.00%
AUM
8.06B USD
Expense ratio
0.43%
Price / 1D
$60.795-0.30%
Dimensional - US Core Equity 1 ETF logoDimensional - US Core Equity 1 ETFDCOR
Market value
7.93K
Weight
0.00%
AUM
3.51B USD
Expense ratio
0.14%
Price / 1D
$84.42-0.14%
Dimensional - US Core Equity 2 ETF logoDimensional - US Core Equity 2 ETFDFAC
Market value
3.86K
Weight
0.00%
AUM
49.31B USD
Expense ratio
0.17%
Price / 1D
$45.505-0.23%
Avantis Total Equity Markets ETF 1 logoAvantis Total Equity Markets ETF 1AVTM
Market value
2.34K
Weight
—
AUM
795.5M USD
Expense ratio
0.23%
Price / 1D
$55.3082-0.51%

Continue in GoAI

Research VRCA

research.disclaimer